FDA Adverse Event Injury Summary report: N

INTRALASE FS2

MDR report key: 7528590 · Received May 20, 2018

Report

Report Number
3006695864-2018-01120
Event Type
Injury
Date Received
May 20, 2018
Date of Event
April 20, 2018
Report Date
June 12, 2018
Manufacturer
JOHNSON & JOHNSON SURGICAL VISION, INC
Product Code
HNO
PMA / PMN Number
K060372
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
TX, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

(B)(4). A REVIEW OF RECORDS RELATED TO THE DEVICE INCLUDING COMPLAINT TRENDING, AND RISK DOCUMENTATION WILL BE PERFORMED. UPON COMPLETION OF THIS REVIEW, IF THERE IS ANY FURTHER RELEVANT INFORMATION OBTAINED, A SUPPLEMENTAL MEDWATCH WILL BE FILED. ALL PERTINENT INFORMATION AVAILABLE TO JOHNSON & JOHNSON SURGICAL VISION, INC. HAS BEEN SUBMITTED.

Additional Manufacturer Narrative · 1

IN INITIAL REPORT, IT WAS INDICATED THERE WAS NO ADDITIONAL INFORMATION PROVIDED, HOWEVER, ADDITIONAL INFORMATION WAS PROVIDED THAT STRIAE WAS THE ISSUE REPORTED AND WAS INCLUDED IN THE INITIAL REPORT. ALL PERTINENT INFORMATION AVAILABLE TO JOHNSON & JOHNSON SURGICAL VISION, INC. HAS BEEN SUBMITTED.

Description of Event or Problem · 1

IT WAS REPORTED THAT A LASER VISION CORRECTION PATIENT HAD SURGERY ON (B)(6) 2018 AND ON (B)(6) 2018 WAS PRESENTED WITH STRIAE. A FLAP LIFT AND IRRIGATION WAS PERFORMED IN THE RIGHT EYE (OD) POST TREATMENT. IT WAS STATED THAT THE PATIENT HAD NO LOSS OF BEST CORRECTED VISUAL ACUITY (BCVA). PATIENT REPORTED THE SYMPTOMS ARE NOT INTERFERING WITH DAILY ACTIVITIES. ALTHOUGH ATTEMPTS WERE MADE FOR ADDITIONAL INFORMATION, NONE HAS BEEN PROVIDED. BCVA FROM (B)(6) 2018: RIGHT EYE PRE-OP 20/20 -.75 X-.50 X 4, LEFT EYE PRE-OP 20/20 -1.00 X -.25 X 9. THIS REPORT IS FOR THE FEMTO LASER EQUIPMENT. A SEPARATE REPORT WILL BE FILED FOR THE EXCIMER LASER EQUIPMENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
371043 INTRALASE FS2 FEMTOSECOND LASER HNO JOHNSON & JOHNSON SURGICAL VISION, INC 20003D

Patients

Seq Age Sex Outcome Treatment
1 55 YR Required Intervention